Radar · Immunotherapy in United States
Best Immunotherapy Companies in United States
The 1069 best Immunotherapy companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Novavax.
By Riya SenguptaFinancials
1069companies tracked
$53.9Bdisclosed funding
0unicorns
770have raised
Tracking the best Immunotherapy companies in the United States, this directory covers 1,069 firms with $53.9B in total disclosed funding, ranked by equity raised and recent momentum. The global immunotherapy market sat at roughly $13.8B in 2021 and is compounding at 13.8% annually, driven by rising autoimmune disease prevalence and accelerating cancer research investment. That growth rate isn't just a talking point, it's showing up in actual filings.
Across 20 validated filers, combined revenue hits $659M, though the median sits at just $4M with flat YoY growth. The spread is what you should pay attention to. Tg Therapeutics pulled $205M at +70% YoY, Merrimack Pharmaceuticals filed $144M at +62%, and on the net income side, Tg Therapeutics earned $20M, seven times the sector median of $3M. Summit Therapeutics, one of the directory's top-funded names at $713M raised, earned $10M net, three times the median. I'd note that hot themes right now are checkpoint inhibitors, cancer vaccines, and T-cell lymphoma, areas where clinical trial momentum keeps building. Active backers include NIH, HHS, OrbiMed, and RA Capital Management.
Sources & further reading
- Adult survivors of childhood cancer at higher risk for meningiomas
- Top 10 'allergy capitals' of the US, plus 4 tips to manage symptoms
- Climate change causes longer pollen seasons in capital cities
FLIAR INTELLIGENCE · IMMUNOTHERAPY × UNITED STATES
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
355kcombined LinkedIn audience
36%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Immunotherapy companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | 99 | Maky Zanganeh CEO | WordPress Block EditorWordPressMySQL+18 | 11 signals ▼45% M&A · Contracts · Acquisition | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 2 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 17 mo ago | 1 | — | Apple iCloud MailBootstrapAmazon Web Services+20 | 7 signals ▼50% Earnings · Funding · Leadership | — | — |
| 3 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +9% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — | — |
| 4 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | 224 224 → 233 (+4%) · sector median +9% | Stan Riddell Co-Founder | WordPressMySQLPHP+16 | — | 163 patents Patents concentrated in chemistry & materials | — |
| 5 | Inhibrx Antibody-based immunotherapeutics for cancer and infectious diseases 45Funding top 25%Patents top 29%Product top 32%Innovation top 33% All 11 signals ▾Fundingtop 25% Patentstop 29% Producttop 32% Innovationtop 33% Techtop 42% Moatbottom 49% Growthbottom 43% Marketbottom 41% Globalbottom 40% Newsbottom 32% Fin. healthbottom 31% Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $469M | 15 mo ago | 112 112 → 111 (-1%) · sector median +9% | — | WordPressBugHerdMySQL+34 | — | 499 patents Engineering multispecific therapeutic proteins (antibodies, DR5, serpin fusions) for immune modulation | 1 launch |
| 6 | Agenusbio Developer of immunotherapies to treat cancer 60Funding top 20%Tech top 34%Product top 35%Market top 37% All 11 signals ▾Fundingtop 20% Techtop 34% Producttop 35% Markettop 37% Moattop 44% Partnerstop 45% Fin. healthtop 48% Growthtop 50% Newsbottom 47% Talentbottom 40% Globalbottom 39% Funding: Raised $441M across 12 rounds · 12 rounds over 17 yrs (0.7/yr) Tech: 41 technologies across 6/8 capability areas · Cloud: Cloudflare, Fastly rank vs industry peers · Fliar Intelligence Index 60/100 | $441M | 12 mo ago | 533 | Garo Armen Chairman & CEO | WordPressMySQLMariaDB+19 | 10 signals ▼74% Earnings · Announcements · Leadership | — | — |
| 7 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | Andrew Schiermeier Chief Executive Officer | WordPressApple iCloud MailMySQL+16 | — | — | — |
| 8 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 8 mo ago | — | Mark Attanasio Co-Founder | — | — | — | — |
| 9 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | 949 | Henry Ji Co-Founder & CEO | — | — | 1,073 patents Patents concentrated in health & consumer products | — |
| 10 | Be Bio Developer of B cell therapies for multiple therapeutic areas 50Funding top 22%Moat top 31%Market top 48%Global bottom 36% All 4 signals ▾Fundingtop 22% Moattop 31% Markettop 48% Globalbottom 36% Funding: Raised $264M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $264M | 17 mo ago | 103 | — | — | — | — | — |
| 11 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | 14 | — | — | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 12 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +9% | — | WordPressMySQLPHP+13 | — | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 13 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | 12 12 → 23 (+92%) · sector median +9% | — | Apple iCloud MailMicrosoft 365Bootstrap+8 | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 14 | Xilio Therapeutics Developer of immunotherapies for the treatment of cancer 67Funding top 25%Growth top 27%Moat top 28%Fin. health top 41% All 9 signals ▾Fundingtop 25% Growthtop 27% Moattop 28% Fin. healthtop 41% Markettop 43% Techtop 45% Talentbottom 49% Newsbottom 46% Globalbottom 39% Funding: Raised $233M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Growth: Headcount 30 → 72 (+140%) across vintages · Revenue +590% YoY rank vs industry peers · Fliar Intelligence Index 67/100 | $233M | 16 mo ago | 72 72 → 96 (+33%) · sector median +9% | Rene Russo CEO | WordPressDrupalMySQL+31 | 3 signals ▼40% Earnings · Announcements | — | — |
| 15 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | — | Ken Song CEO | WordPressMySQLPHP+15 | 4 signals M&A | — | — |
| 16 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | — | Dave Johnson Founder & CEO | — | — | — | — |
| 17 | Sanaria Developer of whole-parasite malaria vaccines for infectious diseases 48Funding top 23%Patents top 33%Moat top 41%Innovation top 46% All 8 signals ▾Fundingtop 23% Patentstop 33% Moattop 41% Innovationtop 46% Growthtop 47% Marketbottom 44% Techbottom 44% Globalbottom 37% Funding: Raised $188M across 44 rounds · 44 rounds over 21 yrs (2.1/yr) Patents: 134 patents matched (strict assignee match) · 16 filings since 2022 vs 46 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $188M | 9 mo ago | 77 | — | WordPressMySQLPHP+21 | — | 134 patents Malaria vaccine production, sporozoite cryopreservation, and vector storage technologies | — |
| 18 | NextCure Developer of next-generation immuno-oncology-based drugs 69News top 21%Funding top 23%Patents top 25%Moat top 26% All 11 signals ▾Newstop 21% Fundingtop 23% Patentstop 25% Moattop 26% Growthtop 30% Innovationtop 32% Fin. healthtop 43% Markettop 44% Partnerstop 45% Techbottom 46% Globalbottom 42% News: 7 BI events in 12 mo (of 19 tracked, 5 types) · 2 high-value events (IPO/M&A/funding/contracts) in 12 mo Funding: Raised $175M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 69/100 | $175M | 7 mo ago | 87 | — | WordPressDrupalMySQL+24 | 7 signals Announcements · Earnings · Funding | 77 patents Therapeutic antibodies and ADCs targeting novel immune checkpoints for cancer treatment | — |
| 19 | Attovia Developer of antibody-based therapeutics for immune-mediated diseases and oncology 48Funding top 19%Talent top 28%Moat top 38%Global bottom 38% All 5 signals ▾Fundingtop 19% Talenttop 28% Moattop 38% Globalbottom 38% Marketbottom 37% Funding: Raised $165M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $165M | 14 mo ago | — | Zaneta Odrowaz Co-Founder | — | — | — | — |
| 20 | Marker Therapeutics Developer of T-cell based therapeutics for cancer treatment 42Talent top 15%Funding top 18%News top 47%Tech top 50% All 9 signals ▾Talenttop 15% Fundingtop 18% Newstop 47% Techtop 50% Moattop 50% Marketbottom 43% Growthbottom 40% Globalbottom 32% Fin. healthbottom 29% Talent: Analyst team rating 5/5 Funding: Raised $154M across 23 rounds · 23 rounds over 10 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $154M | 9 mo ago | 67 | — | DrupalApple iCloud MailMicrosoft 365+22 | 3 signals Earnings | — | — |
| 21 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 13 mo ago | 33 | Clifford Stocks Founder & CEO | — | — | 56 patents Therapeutic antibodies targeting LILRB2 for immune checkpoint modulation in cancer. | — |
| 22 | Arthrosi Therapeutics Developer of therapeutics for gout, chronic kidney diseases, and oncology 22Funding top 26%News top 46%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 26% Newstop 46% Moattop 48% Talentbottom 49% Techbottom 43% Globalbottom 37% Marketbottom 24% Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY rank vs industry peers · Fliar Intelligence Index 22/100 | $140M | 12 mo ago | 11 | Litain Yeh Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+24 | — | — | — |
| 23 | Wugen Developer of CAR-T cell therapy for treatingT-cell malignancies 64Talent top 15%Funding top 21%Patents top 26%Moat top 28% All 9 signals ▾Talenttop 15% Fundingtop 21% Patentstop 26% Moattop 28% Innovationtop 30% Techbottom 45% Marketbottom 43% Globalbottom 40% Newsbottom 22% Talent: Analyst team rating 5/5 Funding: Raised $136M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $136M | 9 mo ago | 81 | — | WordPressMySQLPHP+24 | — | 41 patents Immunotherapy platforms: memory NK cell expansion, CD3‑engineered immune cells, CARs, bispecific antibodies | 1 job opening |
| 24 | Precision BioSciences Developer of gene editing therapies to treat rare genetic diseases 57Product top 19%Funding top 21%Moat top 32%Patents top 36% All 11 signals ▾Producttop 19% Fundingtop 21% Moattop 32% Patentstop 36% Newstop 38% Markettop 39% Techtop 41% Innovationtop 42% Growthbottom 47% Globalbottom 42% Fin. healthbottom 39% Product: 3 distinct product lines · Company stage: Public Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $136M | 3 mo ago | 236 | — | DrupalApple iCloud MailMicrosoft 365+23 | 3 signals ▲50% Regulatory · Earnings · Capital raise | 68 patents Therapeutic genome editing using engineered meganucleases and engineered T‑cell therapies | 1 launch |
| 25 | Cartesian Therapeutics Pioneering mRNA cell therapies for autoimmune diseases, expanding treatment possibilities 48Funding top 24%Moat top 37%Fin. health top 42%Growth top 44% All 8 signals ▾Fundingtop 24% Moattop 37% Fin. healthtop 42% Growthtop 44% Markettop 49% Newsbottom 38% Globalbottom 32% Techbottom 26% Funding: Raised $133M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Top 15% by revenue among 13 tracked Immunotherapy companies · Editorial + unicorn rating 2/10 rank vs industry peers · Fliar Intelligence Index 48/100 | $133M | 12 mo ago | 26 | — | Cart FunctionalityWordPressMySQL+13 | 3 signals ▼75% Announcements | — | 1 partnership |
| 26 | Bryn Pharma Developer of nasal based epinephrine for anaphylaxis 10Funding top 26%Talent bottom 49%Global bottom 29%News bottom 24% All 6 signals ▾Fundingtop 26% Talentbottom 49% Globalbottom 29% Newsbottom 24% Marketbottom 20% Techbottom 17% Funding: Raised $123M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 10/100 | $123M | 14 mo ago | 10 | David Dworaczyk Retired CEO: Corporate Advisor/Consultant to Bryn Pharma | PleskWindows ServerMicrosoft ASP.NET+10 | — | — | — |
| 27 | Corner Therapeutics Developer of immuno-therapeutics to treat cancer 24Funding top 34%Moat top 42%Talent top 45%Global bottom 32% All 5 signals ▾Fundingtop 34% Moattop 42% Talenttop 45% Globalbottom 32% Marketbottom 31% Funding: Raised $105M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 24/100 | $105M | 8 mo ago | 16 16 → 28 (+75%) · sector median +9% | Andrew Bellinger Co-Founder | — | — | — | — |
| 28 | Vyriad Developer of oncolytic-virus-based immunotherapies for cancer treatment 50Patents top 20%Funding top 21%Innovation top 25%Moat top 32% All 7 signals ▾Patentstop 20% Fundingtop 21% Innovationtop 25% Moattop 32% Techbottom 43% Globalbottom 37% Marketbottom 36% Patents: 70 patents matched (strict assignee match) · 56 filings since 2022 vs 14 in 2017-21 Funding: Raised $100M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 5 mo ago | 37 | — | WordPressMySQLPHP+18 | — | 70 patents Engineered rhabdoviral vectors for cancer immunotherapy and viral antibody diagnostics | — |
| 29 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | — | WordPressMySQLPHP+28 | — | — | — |
| 30 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 2 mo ago | 54 | John Mulligan Founder & CEO | WordPressMySQLPHP+21 | — | — | — |
| 31 | STAR Therapeutics Developer of antibody therapies for multiple diseases 40Funding top 21%Moat top 42%Talent bottom 49%News bottom 45% All 6 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Newsbottom 45% Marketbottom 42% Globalbottom 38% Funding: Raised $90.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $90M | 8 mo ago | 43 | Adam Rosenthal Founder & CEO | — | — | — | — |
| 32 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 2 mo ago | 19 | Stephen B Chief Executive Officer | DrupalPHPparticles.js+25 | 19 signals Earnings · Funding · M&A | — | — |
| 33 | Azalea Therapeutics Developer of precision genome engineering technologies for in vivo cell therapies 62Talent top 23%Funding top 26%Global bottom 33% All 3 signals ▾Talenttop 23% Fundingtop 26% Globalbottom 33% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $82.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 7 mo ago | — | Jenny H Co-Founder | — | — | — | 1 expansion |
| 34 | Crossbow Developer of antibody therapies for cancer treatment 42Funding top 21%Moat top 36%News top 38%Talent top 38% All 8 signals ▾Fundingtop 21% Moattop 36% Newstop 38% Talenttop 38% Innovationtop 48% Patentsbottom 49% Globalbottom 39% Marketbottom 35% Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $80M | 3 mo ago | 24 | Geraldine Paulus Co-Founder | — | 3 signals Funding | 21 patents High‑precision MEMS inertial sensors and power‑efficient wireless tracking technologies | — |
| 35 | EpiBiologics Developer of antibody-based targeted therapies to treat multiple diseases 45Funding top 21%Talent top 38%Moat top 39%Innovation top 42% All 7 signals ▾Fundingtop 21% Talenttop 38% Moattop 39% Innovationtop 42% Patentstop 42% Globalbottom 37% Marketbottom 34% Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $73M | 5 mo ago | 22 | Josef Gramespacher Co-Founder | — | — | 13 patents Bispecific antibody therapeutics for targeted degradation of EGFR and cMET receptors | 1 job opening |
| 36 | Gliknik Discovering and developing innovative biologics for immune disorders and cancers 22Funding top 21%Moat top 21%Product top 25%Patents top 31% All 9 signals ▾Fundingtop 21% Moattop 21% Producttop 25% Patentstop 31% Innovationtop 33% Globalbottom 36% Newsbottom 22% Marketbottom 20% Techbottom 16% Funding: Raised $60.3M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 246 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $60M | 10 mo ago | 6 | — | — | — | 246 patents Engineered multimeric Fc fusion proteins for enhanced complement activation and therapeutic antibodies | — |
| 37 | Link Cell Therapies Developer of CAR-T cell therapies for the treatment of cancer 11Funding top 29%Tech bottom 41%Global bottom 29%Market bottom 19% All 4 signals ▾Fundingtop 29% Techbottom 41% Globalbottom 29% Marketbottom 19% Funding: Raised $60.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) Tech: 19 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 6 mo ago | 8 | — | WordPress Block EditorWordPressMySQL+16 | — | — | — |
| 38 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 8 mo ago | 41 | — | — | — | 128 patents Immune checkpoint antibody therapeutics, especially anti‑CTLA‑4 combos for cancer treatment | 1 job opening |
| 39 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 1 mo ago | 9 | — | WordPressMySQLPHP+18 | — | — | 1 job opening · 1 partnership · 1 award |
| 40 | SAB Biotherapeutics Developer of immunotherapeutics to treat infectious and autoimmune diseases 21Funding top 25%News top 38%Tech top 46%Global bottom 37% All 8 signals ▾Fundingtop 25% Newstop 38% Techtop 46% Globalbottom 37% Moatbottom 37% Marketbottom 35% Growthbottom 32% Fin. healthbottom 26% Funding: Raised $49.0M across 10 rounds · 10 rounds over 12 yrs (0.8/yr) News: 4 BI events in 12 mo (of 36 tracked, 7 types) · +33% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $49M | 10 mo ago | 56 56 → 88 (+57%) · sector median +9% | — | DrupalApple iCloud MailMicrosoft 365+24 | 4 signals ▲33% Leadership · Earnings | — | — |
| 41 | LTZ Therapeutics Developer of immunotherapies to treat cancer and other diseases 35Funding top 26%Moat top 39%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 39% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $47M | 1 mo ago | 23 | Martin Treder Co-Founder | — | — | — | 2 job openings |
| 42 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | 9 | Stephen Webber Co-Founder | — | — | — | — |
| 43 | TuHURA Biosciences Developer of immunotherapies for the treatment of cancer 42Funding top 20%Talent top 38%Moat top 39%Growth top 45% All 8 signals ▾Fundingtop 20% Talenttop 38% Moattop 39% Growthtop 45% Techbottom 47% Newsbottom 39% Globalbottom 36% Marketbottom 32% Funding: Raised $37.8M across 11 rounds · 11 rounds over 8 yrs (1.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $38M | 7 mo ago | — | Patricia Lawman Co-Founder | WordPressMySQLPHP+16 | 4 signals ▼67% Earnings | — | — |
| 44 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 5 mo ago | 31 31 → 25 (-19%) · sector median +9% | William Ho Founder & CEO | DrupalPHPZURB Foundation+22 | — | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies for cancer treatment | — |
| 45 | Rational Vaccines Developer of live attenuated viral immunotherapeutic and prophylactic vaccine candidates 29Funding top 28%Moat top 38%Patents top 40%Innovation top 46% All 8 signals ▾Fundingtop 28% Moattop 38% Patentstop 40% Innovationtop 46% Talentbottom 49% Techbottom 42% Globalbottom 37% Marketbottom 25% Funding: Raised $30.6M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 8 mo ago | 18 18 → 11 (-39%) · sector median +9% | Agustin Fernandez Founder & CEO | WordPressMySQLPHP+17 | — | 9 patents Serological SARS‑CoV‑2 diagnostics and recombinant vaccine platforms for intracellular pathogens. | — |
| 46 | Incyclix Bio A next-generation cell cycle control company advancing precision treatments for cancer 21Funding top 25%Talent top 28%Moat top 39%Tech bottom 31% All 6 signals ▾Fundingtop 25% Talenttop 28% Moattop 39% Techbottom 31% Globalbottom 29% Marketbottom 20% Funding: Raised $30.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 21/100 | $30M | 2 mo ago | 6 | Patrick Roberts Co-Founder & CEO | WordPressMySQLPHP+14 | — | — | — |
| 47 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | 3 | — | — | — | 26 patents Patents concentrated in chemistry & materials | — |
| 48 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +9% | — | WordPress Block EditorWordPressMySQL+15 | 16 signals ▲45% Board · Leadership · Earnings | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 49 | Leap Therapeutics Developing targeted and immuno-oncology therapeutics for cancer patients 35Product top 14%Funding top 30%Innovation top 34%Tech top 49% All 10 signals ▾Producttop 14% Fundingtop 30% Innovationtop 34% Techtop 49% Moatbottom 45% Newsbottom 42% Growthbottom 39% Globalbottom 37% Marketbottom 35% Fin. healthbottom 30% Product: 4 distinct product lines · Company stage: Public Funding: Raised $24.7M across 7 rounds · 7 rounds over 15 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $25M | 8 mo ago | 44 | — | DrupalPHPAmazon Web Services+20 | — | — | — |
| 50 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 2 mo ago | 3 | Kerry Wilson Co-Founder | — | — | — | — |
Top 12 Immunotherapy companies in United States
#1
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Public · Vancouver, Washington · founded 2002 · 12 employees
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 17%Growth
top 35%Patents
top 36%Innovation
top 44%Moat
bottom 49%Global
bottom 36%Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) · Last round Post IPO (Mar 2026)
Growth: Fresh capital in last 24 mo
Patents: 107 patents matched (strict assignee match) · 25 filings since 2022 vs 49 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Natera) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
Investors
Cool Blue Capital, Centrecourt Asset Management, 4-Good Ventures
Tech stack
Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapFancyboxGoogle Analytics
#2
Public · Menlo Park, California · founded 2003 · 99 employees$713Mraised▾
Public · Menlo Park, California · founded 2003 · 99 employees
Developer of therapeutics for oncology and rare diseases. It offers Ivonescimab which combines the effects of immunotherapy via a blockade of PD-1 with the anti-VEGF effect for the treatment of non-small cell lung cancer.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Partners
top 31%Funding
top 33%Product
top 35%News
top 37%Tech
top 45%Growth
bottom 43%Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Post IPO (Oct 2025)
Product: 0 product launch events in 12 mo, 1 the year before · Company stage: Public
Audience (LinkedIn): 58k LinkedIn followers — 16.4% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$228M
- Sep 2024Post IPO$235M
- Jun 2024Post IPO$200M
- Nov 2020Post IPO$50M
Founders & team
Investors
Akeso
Tech stack
CloudflareFancyboxGodaddyGoogle Font ApiHstsJquery
#3
Public · Durham, North Carolina · founded 2006 · 236 employees$135.7Mraised▾
Public · Durham, North Carolina · founded 2006 · 236 employees
Developer of gene editing therapies to treat rare genetic diseases. The company utilizes novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination. The company's pipeline include therapies for Hepatitis B, duchenne muscular dystrophy, and more.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 19%Funding
top 21%Moat
top 32%Patents
top 36%News
top 38%Market
top 39%Product: 3 distinct product lines · Company stage: Public
Funding: Raised $136M across 9 rounds · 9 rounds over 16 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Moat: Editorial + unicorn rating 6/10 · IP moat: 68 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 6.8% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Post IPO$7.5M
- Jun 2022Post IPO$75M
- Mar 2019Conventional Debt$39.5M
- Jun 2018Series B$110M
Investors
NIST, NIH, North Carolina, Treasury, VenBio, Baxter
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services
#4
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers — 2.4% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#5
Public · San Francisco, California · founded 2011 · 19 employees$88.2Mraised▾
Public · San Francisco, California · founded 2011 · 19 employees
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 28%News
top 36%Growth
top 42%Tech
top 49%Moat
bottom 43%Talent
bottom 41%Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Mar 2026)
News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 5,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding rounds
- Mar 2026Post IPO$6M
- Mar 2026Post IPO$2M
- Feb 2020Series B$83.2M
- 2015Series A—
Founders & team
Investors
F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Versant Ventures, Quan Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#6
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Series B · Seattle, Washington · founded 2021 · 54 employees
Manufacturer of cytokine based drugs
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 22%Talent
bottom 49%Tech
bottom 45%Global
bottom 43%Market
bottom 36%Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) · Last round Series B (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Tech: 24 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
Founders & team
Investors
Vivo Capital, Roche, RiverVest Venture Partners, Digitalis Ventures, 3x5 Partners, Codon Capital
#7
Series B · Redwood City, California · founded 2021 · 23 employees$47Mraised▾
Series B · Redwood City, California · founded 2021 · 23 employees
Developer of immunotherapies to treat cancer and other diseases. The company focuses on the development of immunotherapies that are capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science technology.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Moat
top 39%Talent
bottom 49%Market
bottom 40%Global
bottom 36%Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Finance Coordinator (R&D), Medical/Sr. Med Director (MD) – Early Clinical Development
Activity (LinkedIn): 1 partnerships (incl. GlisoSmithKline (GSK)) announced in 12 mo
Funding rounds
- May 2026Series B$38M
- Jul 2024Series A$20M
- May 2023Seed$10M
- Apr 2022Seed$17M
Founders & team
Investors
Qiming Venture Partners, Shunwei Capital, K2 Venture Capital, Tigermed, Lapam Capital, K2VC
#8
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees$50Mraised▾
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees
Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.
Fliar Intelligence Index™ 16how this company ranks against its industry peers
Funding
top 32%Moat
top 39%Tech
bottom 43%Global
bottom 38%Market
bottom 25%News
bottom 21%Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Tech: 21 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Hsts, Http/3
Audience (LinkedIn): 7k LinkedIn followers — 2.0% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Process & Analytical Development Specialist
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Cryoport) announced in 12 mo
Funding rounds
- Apr 2026Series A$28M
- Jul 2023Seed$19.2M
- Feb 2023Seed$7M
- Apr 2021Seed$16M
Investors
DongKoo Bio& Pharma, BRV Capital Management, Ignite Innovation
#9
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees$80Mraised▾
Series B · Cambridge, Massachusetts · founded 2021 · 24 employees
Developer of antibody therapies for cancer treatment. The company is advancing the development of novel therapies that potently target peptide-loaded major histocompatibility complexes (pMHCs) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 21%Moat
top 36%News
top 38%Talent
top 38%Innovation
top 48%Patents
bottom 49%Funding: Raised $80.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 21 patents · Soonicorn
News: 3 BI events in 12 mo (of 4 tracked, 2 types) · Top themes: Funding
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- Mar 2026Series B$77M
- Sep 2025Series A$30.2M
- Jul 2023Series A$80M
Founders & team
Investors
Pfizer, Polaris Partners, BVF Partners, Mirae Asset Venture Investments, Mirae Asset, Lilly
#10
Series B · San Diego, California · founded 2020 · 14 employees$259.6Mraised▾
Series B · San Diego, California · founded 2020 · 14 employees
Provider of the drug for the treatment of oncology and autoimmune disorders. The company is involved in drug design and development based on small molecules.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 20%Patents
top 21%Innovation
top 23%Moat
top 26%News
bottom 42%Global
bottom 42%Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Nov 2025)
Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 133 patents (top 21% of patent-holders) · 133 filings since 2022 vs 0 in 2017-21
Audience (LinkedIn): 9k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Principal Programmer, Statistical Programming, Director/Senior Director, Medical Affairs
Funding rounds
- Nov 2025Series B$84.2M
- Dec 2023Series B$100M
- Mar 2021Series A$71M
Investors
Cormorant Asset Management, Orbimed, Vivo Capital, Colt Ventures, Plaisance Capital Management, H&D Asset Management
#11
Acquired · San Francisco, California · founded 2011 · 3 employees$26.7Mraised▾
Acquired · San Francisco, California · founded 2011 · 3 employees
Developer of resistance mechanism inhibitors to treat cancer. It targets multiple hallmarks of cancer progression and have demonstrated efficacy as monotherapy and in strategic combinations. The lead drug program OS2966 therapeutic antibody blocking a cell surface receptor for the treatment of glioblastoma, ovarian, pancreatic cancer, and malignant meningioma.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Patents
bottom 48%Global
bottom 42%Innovation
bottom 33%Market
bottom 18%Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series A (May 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents
Patents: 26 patents matched (strict assignee match) · 4 filings since 2022 vs 12 in 2017-21 · Latest publication 2023
Audience (LinkedIn): 1k LinkedIn followers
Funding rounds
- May 2022Series A$3.5M
- Nov 2020Conventional Debt$250K
- Sep 2020Series A$3.2M
- Jan 2020Grant (prize money)$300K
Investors
National Cancer Institute, Connecticut Innovations, Navation, KICC, HHS, JLABS
#12
Series C · Los Angeles, California · founded 2019$350Mraised▾
Series C · Los Angeles, California · founded 2019
Developer of antibody-based therapeutics for the treatment of cancer. The company's lead candidate, TORL-1-23, is a CLDN6-directed antibody-drug conjugate for patients across multiple cancer types. Also, it is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 16%Moat
top 31%Talent
bottom 49%Market
bottom 40%Global
bottom 29%Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series C (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Oct 2025Series C$96M
- Apr 2024Series B$158.3M
- Apr 2023Series B$158M
Founders & team
Investors
Goldman Sachs Asset Management, Deep Track Capital, Moore Ventures, Cowen, Bristol-Myers Squibb, Vertex Ventures HC
Funding & investor landscape
$53.9Btotal disclosed funding
755companies funded
3,510disclosed rounds
8rounds last 90 days
Most active investors
Notable founders
Maky Zanganeh
CEO · Summit
Ken Song
CEO · Candid Therapeutics
Stephen B
Chief Executive Officer · TEMPEST THERAPEUTICS
John Mulligan
Founder & CEO · Bonum Therapeutics
Martin Treder
Co-Founder · LTZ Therapeutics
Geraldine Paulus
Co-Founder · Crossbow
Briggs Morrison
CEO · Crossbow
Mark Attanasio
Co-Founder · TORL BioTherapeutics
Dave Johnson
Founder & CEO · Solve Therapeutics
Stan Riddell
Co-Founder · Lyell Immunopharma
Crystal Mackall
Co-Founder · Lyell Immunopharma
Patrick Roberts
Co-Founder & CEO · Incyclix Bio
Prism market signals · United States · country-scoped Prism corpus, 1,146,706 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 55% → 62% across 2008–2026.
top research entities
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
leading researchers
Sarkar, Subhankar · F. Stephen Hodi · Jedd D. Wolchok · Michael A. Postow · Thomas Powles · Yan-Ruide Li · Abdullah Esmail · Julie R. Brahmer
▲
Breakthroughs3,482 · 25%
▲ 22%→25% share
▲1.1× share momentum0 median citations89% since 2021mostly methods-led
Tumor microenvironment research is surging — U.S. breakthrough papers grew 16-fold (30→481), signaling rapid mechanistic discovery.
rising sub-themes (early→recent)
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
Newly emergingBreast cancer 0→90 · Reprogramming 0→86 · Flow cytometry 0→44
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements6,585 · 47%
▼ 51%→47% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Transcriptome analysis newly emerged in advancements at 108 papers, reflecting genomic tools reshaping U.S. immunotherapy clinical translation.
rising sub-themes (early→recent)
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
Newly emergingTranscriptome 0→108 · Retrospective cohort study 0→62 · Phases of clinical research 0→59
Landmark Improved Survival with Ipilimumab in Patients with Metastatic Melanoma · 15,037 cites
▼
Concerns2,356 · 17%
▲ 16%→17% share
▲1.1× share momentum0 median citations87% since 2021mostly empirical
Clinical trial concerns are intensifying — papers flagging trial-related issues grew 19-fold (11→209) across U.S. immunology research.
rising sub-themes (early→recent)
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Newly emergingMultiple myeloma 0→54 · MEDLINE 0→49 · Refractory (planetary science) 0→39
Landmark PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer · 30,895 cites
RESEARCH HOTSPOTS · United States
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1049 · +0.47
New York931 · +0.44
SF Bay Area496 · +0.50
Philadelphia473 · +0.46
Chicago379 · +0.45
Los Angeles309 · +0.48
Atlanta261 · +0.45
San Diego234 · +0.47
Seattle195 · +0.48
Pittsburgh179 · +0.43
PATENT SIGNAL · United States
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
10,389 filings4,528 assigneespeak 1314/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST223
Common questions
How many Immunotherapy companies are there in United States?
Radar tracks 1069 indexable Immunotherapy companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in United States?
The Immunotherapy companies in United States on this list have raised a combined $53.9B in disclosed equity funding across 755 funded companies.
Which is the highest-funded Immunotherapy company in United States?
Novavax is the highest-funded Immunotherapy company in United States, with $2.7B in disclosed equity funding.
How many Immunotherapy companies in United States are funded?
755 of the 1069 Immunotherapy companies in United States on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in United States?
None of the Immunotherapy companies in United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in United States Immunotherapy companies?
The most active investors in United States Immunotherapy companies on this list include HHS, NIH, Orbimed, RA Capital Management, Alexandria.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.